Gabapentin as add-on treatment for somatoform disorder: a case report.

Abstract

Somatoform disorder is a relatively common and severe disorder for which pharmacotherapy has been minimally studied. We report a case of 30-year-old woman with treatment-resistant somatoform disorder that was successfully treated with add-on treatment of gabapentin. Our result showed that gabapentin 1800 mg/day could be tried in case of treatment-resistant somatoform disorder as an add-on strategy. However, controlled trials are needed to investigate the effectiveness of gabapentin in the management of this condition.

• Authors: Riccardo Guglielmo, Giovanni Martinotti, Luigi Janiri
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2012 Jan-Feb Vol. 35 Issue 1 Pg. 45-6 ISSN: 1537-162X [Electronic] United States
• PMID: 22240859 (Publication Type: Case Reports, Journal Article)

Chemical References

• Amines
• Anticonvulsants
• Antimanic Agents
• Cyclohexanecarboxylic Acids
• gamma-Aminobutyric Acid
• Gabapentin

Topics

• Adult
• Amines (therapeutic use)
• Anticonvulsants (therapeutic use)
• Antimanic Agents (therapeutic use)
• Cyclohexanecarboxylic Acids (therapeutic use)
• Female
• Gabapentin
• Humans
• Psychiatric Status Rating Scales
• Somatoform Disorders (drug therapy)
• gamma-Aminobutyric Acid (therapeutic use)